Connect with Labcorp at International ISSX Meeting
Sep 21 – Sep 24, 2025 | Chicago, IL, USA
With more than 80 years of toxicology experience, Labcorp is focused on delivering the answers you need to move your program to the next milestone. Our global capacity, flexible scheduling and rapid study initiation creates a streamlined approach to nonclinical services, which means successful design and execution of your program across discovery, safety pharmacology, toxicology, pathology, bioanalysis, radiopharmaceuticals, drug metabolism and pharmacokinetics.
Propel your development program with our comprehensive DMPK solutions
In vitro metabolism
In vivo metabolism
MetID
Pharmacometrics
Meet our team at ISSX 2025
Booth #109:
Our commercial and scientific team members will be on-site to provide comprehensive and strategic insights to help reduce risk and move your program more efficiently across critical milestones.
Posters
| Session Date & Time | Title |
Abstract # |
| Monday, September 22 12:00 PM - 3:00 PM |
NAMS in DMPK: Case Studies and Context of Use Applications | P45 |
| Monday, September 23 12:30 PM - 2:30 PM |
Development and Implementation of a Mouse Bile-duct Cannulated Model for use in DMPK Studies | 120 |
| Tuesday, September 23 12:30 PM - 2:30 PM |
Increasing Animal Reuse: Novel Approaches to Achieving a 3RS Reduction of all Naïve Animal Species used Across Nonclinical Studies | P54 |
Presentation
| Session Date & Time | Title |
| Wednesday, September 24 12:45 PM - 12:55 PM |
Strategic Advantage: Leveraging NAMs to De-Risk and Accelerate Drug Development |
A review of the global regulatory and governmental drivers, challenges and opportunities to embrace, utilize, and adopt New Approach Methodologies (NAMs). There will be a particular emphasis on US-based activities, including interpretation and commentary on the FDA roadmap announcement. The talk will provide some insight and discussion around where Labcorp see opportunities for accelerating the use of NAMs to support drug development and chemical evaluation in the near, medium and longer terms from the subsequent symposium speakers. Finally, the presentation will highlight:
- DMPK being a cornerstone discipline utilizing NAMs
- Early use of NAMs based DMPK data in decision making is hugely beneficial to de-risking compound development
- Further integration of modelling, in silico, AI, and wider human based MPS and organoid tools in DMPK will be employed in the future to provide greater insights into translatability of NAMs
Regulatory landscapes, and incentives to use NAMs, will evolve as the science matures, building confidence in translation and predictivity of these new approaches.
Learn more at labcorp.com/biopharma/nonclinical.
Labcorp respects your privacy.
Manage your subscriptions.
© 2025 Laboratory Corporation of America® Holdings. All Rights Reserved.